Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biomea Fusion, Inc. (BMEA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures related to its clinical-stage diabetes and obesity programs. As a Nasdaq-listed issuer, Biomea Fusion submits current and periodic reports that describe its investigational therapies, financing transactions, and key corporate developments.
Among the most relevant documents for analysis are Form 8-K current reports, where the company furnishes press releases on quarterly financial results, clinical data updates, and material agreements. Recent 8-K filings detail underwritten offerings of common stock, pre-funded warrants, and common stock warrants, including terms such as exercise prices, beneficial ownership caps, and provisions that apply in fundamental transactions. Other 8-Ks summarize long-term clinical data from the COVALENT-111 study of icovamenib in type 2 diabetes and outline planned trials in insulin-deficient T2D and GLP-1–treated populations.
Investors can also use this page to follow Biomea Fusion’s capital-raising activity under shelf registration statements on Form S-3, as referenced in its 8-K exhibits. These filings explain how the company structures offerings to support development of icovamenib, its oral covalent menin inhibitor, and BMF-650, its investigational oral GLP-1 receptor agonist for obesity.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical and financial disclosures, and potential implications without requiring readers to parse every line of the original documents. Users can quickly review material events, then drill down into full-text SEC filings for deeper due diligence on Biomea Fusion’s regulatory, clinical, and financing history.
Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the award will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, subject to his continued service with the company. Following this grant, he holds 452,512 derivative securities directly.
Biomea Fusion, Inc. reported that Interim CEO and director Michael J.M. Hitchcock received a grant of stock options covering 667,477 shares of Common Stock on April 1, 2026. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the option will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, as long as Hitchcock continues to serve the company through each vesting date. Following this grant, he holds 667,477 derivative securities directly.
Biomea Fusion, Inc. files its annual report describing progress as a clinical-stage company developing oral small-molecule drugs for diabetes, obesity and metabolic disease. Following a 2025 strategic realignment, it now focuses on two core programs: icovamenib and BMF-650.
Lead candidate icovamenib, an oral covalent menin inhibitor, showed durable glycemic benefits in the Phase II COVALENT-111 trial, including a sustained placebo-adjusted HbA1c reduction of 1.5% at week 52 in severe insulin-deficient type 2 diabetes after only 12 weeks of dosing, and 1.8% in a post-hoc GLP-1 RA subgroup. More than 400 subjects have received icovamenib with a generally well-tolerated safety profile and no treatment-related serious adverse events reported.
Two new Phase II trials, COVALENT-211 and COVALENT-212, are enrolling type 2 diabetes patients not at glycemic targets, with a 26‑week primary endpoint readout expected in the fourth quarter of 2026. The company is also running Phase I trial GLP-131 for oral GLP‑1 RA candidate BMF‑650 in obesity, with initial 28‑day weight‑loss data expected in the second quarter of 2026.
Biomea Fusion reported full-year 2025 results and highlighted rapid progress in its diabetes and obesity pipeline. The company posted a net loss of $61.8 million, significantly narrower than $138.4 million in 2024, as research and development expenses fell to $62.0 million from $118.1 million following a strategic focus on core metabolic programs.
As of December 31, 2025, Biomea held $56.2 million in cash, cash equivalents and restricted cash and projects a cash runway into the first quarter of 2027. Clinically, lead menin inhibitor icovamenib showed durable 52‑week HbA1c reductions of about 1.2% in difficult‑to‑treat type 2 diabetes subgroups, with no treatment‑related serious adverse events or discontinuations.
The company initiated two Phase II icovamenib trials in type 2 diabetes with 26‑week endpoints and expects data in the fourth quarter of 2026, and completed 52‑week follow‑up in a Phase II type 1 diabetes study with data expected in the second quarter of 2026. Biomea also advanced oral GLP‑1 candidate BMF‑650 into the Phase I GLP‑131 obesity trial, with initial 28‑day weight‑reduction data anticipated in the second quarter of 2026.
Biomea Fusion filed an 8-K to share an updated corporate presentation outlining its pipeline for diabetes and obesity. The company highlights icovamenib, a potential first-in-class oral menin inhibitor designed to restore beta-cell function in type 2 diabetes, with two Phase II trials (COVALENT-211 and COVALENT-212) underway and 26-week primary endpoint data anticipated in 4Q 2026. Earlier Phase IIa data showed durable HbA1c reductions and increased C-peptide up to 52 weeks after a 12-week course, along with a generally favorable safety profile. Biomea also presents BMF-650, an investigational next-generation oral GLP-1 receptor agonist for obesity that achieved up to about 15% weight loss over 28 days in obese monkeys, with Phase I 28-day weight reduction data in obese volunteers expected in 2Q 2026. The company states it is funded through key readouts for icovamenib and BMF-650 into Q1 2027 and emphasizes large target populations across insulin-deficient diabetes, GLP-1 inadequate responders, and obesity.
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended ownership report showing beneficial holdings of 7,847,232 Biomea Fusion common shares, or 9.9% of the class. The position consists entirely of shares issuable upon exercise of warrants, not currently outstanding stock.
The warrants are subject to a 9.99% beneficial ownership cap, limiting exercises so the reporting persons and their affiliates cannot exceed that level. Heights Capital Management acts as investment manager to CVI Investments and may be deemed to share voting and dispositive power, while both entities disclaim beneficial ownership beyond their pecuniary interest.
Blue Owl Capital Holdings LP filed a Schedule 13G reporting beneficial ownership in Biomea Fusion, Inc. common stock. The firm reports beneficial ownership of 4,451,219 shares of common stock issuable upon exercise of warrants, representing 5.92% of the class.
Blue Owl has shared voting and shared dispositive power over these 4,451,219 warrant shares and no sole voting or dispositive power. The ownership percentage is calculated using 70,703,639 shares of common stock outstanding as of October 31, 2025, increased by the warrant shares. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Biomea Fusion.
Rainer M. Erdtmann filed an amended Schedule 13G reporting beneficial ownership of 2,782,707 shares of Biomea Fusion, Inc. common stock, representing 3.9% of the class as of the measurement date. The holdings include directly owned shares, stock options exercisable within 60 days, and shares held by his children and two independent trusts.
The ownership percentage is based on 70,703,639 shares outstanding as of October 31, 2025, plus 690,677 option shares exercisable within 60 days after December 31, 2025. Erdtmann also notes he resigned on December 19, 2025 from Point Sur Investors’ general partner and is no longer deemed a beneficial owner of securities held by those entities.
Biomea Fusion, Inc. reported that it presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 and made the associated slide deck available on its website. The company also updated its broader corporate investor presentation, which it plans to use with investors, analysts and other third parties.
Both the conference presentation (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) are included as exhibits and are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings. The company highlights that these materials contain forward-looking statements about its product candidates, clinical programs, regulatory plans and anticipated trial data, and emphasizes that actual results may differ due to clinical, regulatory and operational risks described in its SEC reports.
Biomea Fusion, Inc. executive and director Rainer M. Erdtmann reported buying 30,000 shares of Biomea Fusion common stock on 12/11/2025 at a weighted-average price of $1.4333 per share. After this transaction, he directly owns 723,027 shares.
Erdtmann also reports indirect holdings, including 19,400 shares held by a daughter, 20,000 shares held by a son, 20,000 shares held by another daughter, and additional shares held in two independent trusts and two Point Sur investment entities where he has voting or dispositive power but disclaims beneficial ownership beyond any pecuniary interest. He serves as President, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer, and a director of Biomea Fusion. The 30,000-share purchase was executed in multiple trades between $1.42 and $1.46 per share.